E-drug: Third generation oral contraceptives
--------------------------------------------
Dear Colleagues:
On October 18, 1995, the United Kingdom's Committee on Safety of Medicines
(CSM), warned the British public that "third generation" oral
contraceptives containing the progestins desogestrel and gestodene could
double the risk of thromboembolic events compared to older "second
generation" products containing norgestrel, levonorgestrel and
norethindrone. British physicians were told that the third generation oral
contraceptives should not be routinely prescribed and that women should be
offered the choice to switch to the second generation products.
We would like to know the following:
1. Countries in which the marketing approval for third generation oral
contraceptives have been withdrawn.
2. Labeling changes for third generation oral contraceptives, for example
any warnings or restrictions.
Thank you in advance,
Larry D. Sasich, Pharm.D., M.P.H., FASHP
Research Analyst
Public Citizen Health Research Group
1600 20th Street, NW
Washington, DC, USA
Phone: 202-588-7782
FAX: 202-588-7796
Email: lsasich@citizen.org
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.